Brooks Laboratories acquires 44.33% stake in SteriBrooks Penems

18 Sep 2020 Evaluate

Brooks Laboratories has subscribed to 7963 equity shares at the face value of Rs 10 each of SteriBrooks Penems, amounting to 44.33% of the post issue paid-up shares capital of SteriBrooks. The object of the said acquisition is to build a robust carbapenem business with integrated manufacturing capabilities.  

Brooks Laboratories has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials.

Brooks Laboratories Share Price

165.50 3.20 (1.97%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.